Skip to content

Study · Non-randomized trial · n = 126 · 2015

8 results

Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.

Lebret T, Rouanne M, Hublarov O, Jinga V, Petkova L, Kotsev R, Sinescu I, Dutailly P

Therapeutic advances in urology1 Jun 2015Cited by 11 (Europe PMC)

PMID26161143 (opens in a new tab)PMCIDPMC4485417 (opens in a new tab)DOI10.1177/1756287215577329 (opens in a new tab)PepBankPUB-26161143
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In men with advanced prostate cancer, 97.6% achieved testosterone castration after subcutaneous triptorelin at week 4.

    In plain wordsAmong men receiving triptorelin for advanced prostate cancer, 97.6% achieved castration-level testosterone at week 4.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableTestosterone castration at week 4
    Study

    n = 126

    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    11.25 mg at baseline and 13 weeks · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    Castration rate
    97.6%
    week 4

    Source sentences

    Summary
    Of the 126 treated patients, 123 [97.6%; 95% confidence interval (CI): 93.2-99.5)] were castrated 4 weeks after the first subcutaneous injection,
    2 context sentences
    Summary · context
    The co-primary efficacy endpoints were the proportion of patients with a castration level of serum testosterone (<50 ng/dl) after 4 weeks, and of these, those still castrated after 26 weeks.
    Summary · context
    In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later).
  2. 02HumanNon-randomized trialEfficacy outcome

    In men with prostate cancer castrated at week 4, 96.6% maintained castration at week 26 after triptorelin.

    In plain wordsAmong men castrated at week 4 after triptorelin, 96.6% maintained castration at week 26.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableMaintenance of castration at week 26
    Study

    n = 119

    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    11.25 mg at baseline and 13 weeks · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    Maintained castration
    96.6%
    week 26

    Source sentences

    Summary
    and 115/119 patients (96.6%; 95% CI: 91.6-99.1) castrated at 4 weeks maintained castration at 26 weeks.
    2 context sentences
    Summary · context
    The co-primary efficacy endpoints were the proportion of patients with a castration level of serum testosterone (<50 ng/dl) after 4 weeks, and of these, those still castrated after 26 weeks.
    Summary · context
    In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later).
  3. 03HumanNon-randomized trialSafety outcome

    In men with advanced prostate cancer, hot flushes were among the most frequent treatment-related events after triptorelin.

    In plain wordsMen receiving triptorelin reported hot flushes among the most frequent treatment-related events.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedHot flushes
    Study

    n = 126

    Outcome group
    Adverse events · Whole body
    Studied dose
    11.25 mg at baseline and 13 weeks · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The most frequently occurring treatment-related adverse events were typical of gonadotropin-releasing hormone agonist treatment (hot flushes, increased weight, erectile dysfunction and hyperhidrosis).
    1 context sentence
    Summary · context
    In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later).
  4. 04HumanNon-randomized trialSafety outcome

    In men with advanced prostate cancer, increased weight was among the most frequent treatment-related events after triptorelin.

    In plain wordsMen receiving triptorelin reported increased weight among the most frequent treatment-related events.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseIncreased weight
    Study

    n = 126

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    11.25 mg at baseline and 13 weeks · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The most frequently occurring treatment-related adverse events were typical of gonadotropin-releasing hormone agonist treatment (hot flushes, increased weight, erectile dysfunction and hyperhidrosis).
    1 context sentence
    Summary · context
    In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later).
  5. 05HumanNon-randomized trialSafety outcome

    In men with advanced prostate cancer, erectile dysfunction was among the most frequent treatment-related events after triptorelin.

    In plain wordsMen receiving triptorelin reported erectile dysfunction among the most frequent treatment-related events.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedErectile dysfunction
    Study

    n = 126

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    11.25 mg at baseline and 13 weeks · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The most frequently occurring treatment-related adverse events were typical of gonadotropin-releasing hormone agonist treatment (hot flushes, increased weight, erectile dysfunction and hyperhidrosis).
    1 context sentence
    Summary · context
    In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later).
  6. 06HumanNon-randomized trialSafety outcome

    In men with advanced prostate cancer, hyperhidrosis was among the most frequent treatment-related events after triptorelin.

    In plain wordsMen receiving triptorelin reported excessive sweating among the most frequent treatment-related events.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedHyperhidrosis
    Study

    n = 126

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    11.25 mg at baseline and 13 weeks · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The most frequently occurring treatment-related adverse events were typical of gonadotropin-releasing hormone agonist treatment (hot flushes, increased weight, erectile dysfunction and hyperhidrosis).
    1 context sentence
    Summary · context
    In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later).
  7. 07HumanNon-randomized trialEfficacy outcome

    In men with advanced prostate cancer, median PSA decreased by 64.2% and 96.0% at weeks 4 and 26 after triptorelin.

    In plain wordsMen receiving triptorelin had median PSA reductions of 64.2% and 96.0% at weeks 4 and 26 compared with baseline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePSA reduction
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    11.25 mg at baseline and 13 weeks · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    PSA reduction
    64.2%
    week 4
    PSA reduction
    96%
    week 26

    Source sentences

    Summary
    Median prostate-specific antigen levels were reduced by 64.2 and 96.0% at 4 and 26 weeks, respectively.
    1 context sentence
    Summary · context
    In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later).
  8. 08HumanNon-randomized trialEfficacy outcome

    In men with advanced prostate cancer, the probability of maintaining testosterone below 20 ng/dl through week 26 after triptorelin was 90.0%.

    In plain wordsMen receiving triptorelin had a 90.0% probability of maintaining testosterone below 20 ng/dl through week 26.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableMaintenance of testosterone below 20 ng/dl
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    11.25 mg at baseline and 13 weeks · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    Maintenance probability
    90%
    testosterone <20 ng/dl through week 26

    Source sentences

    Summary
    The probability of maintaining a testosterone level <20 ng/dl up to 26 weeks was 90.0% (95% CI: 85.0-95.0).
    1 context sentence
    Summary · context
    In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.